Back to top
more

Gilead Sciences (GILD)

(Delayed Data from NSDQ)

$64.89 USD

64.89
4,647,904

-0.36 (-0.55%)

Updated Jun 11, 2024 04:00 PM ET

After-Market: $64.90 +0.01 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (80 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for GILD

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

Gilead Sciences, Inc. [GILD]

Reports for Purchase

Showing records 461 - 480 ( 525 total )

Company: Gilead Sciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 461

08/11/2011

Company Report

Pages: 7

FDA Approval gives life to Revenue Stream

Provider: BWS Financial

Analyst: KHORSAND H

Price: 25.00

Research Provided by a Third Party

Company: Gilead Sciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 462

07/28/2011

Company Report

Pages: 10

Price: 24.95

Company: Gilead Sciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 463

07/01/2011

Company Report

Pages: 8

Price: 24.95

Company: Gilead Sciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 464

05/10/2011

Company Report

Pages: 10

Price: 24.95

Company: Gilead Sciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 465

04/25/2011

Company Report

Pages: 12

Slowdown in sales of HIV franchise, unfavorable healthcare reforms, currency fluctuations & volatile royalty revenue expected to impact near term growth prospect

Provider: FIRST GLOBAL

Analyst: THOMAS K

Price: 25.00

Research Provided by a Third Party

Company: Gilead Sciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 466

04/25/2011

Company Report

Pages: 9

Price: 24.95

Company: Gilead Sciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 467

03/28/2011

Company Report

Pages: 4

We are dropping coverage of Gilead Sciences (GILD) due to analyst departure.

Provider: WEDBUSH SECURITIES INC.

Price: 10.00

Research Provided by a Third Party

Company: Gilead Sciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 468

02/02/2011

Company Report

Pages: 13

Unfavorable healthcare reforms, currency fluctuations, volatile royalty revenue & delay in combo pill, B-tripla expected to hamper near term growth....

Provider: FIRST GLOBAL

Analyst: THOMAS K

Price: 50.00

Research Provided by a Third Party

Company: Gilead Sciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 469

02/02/2011

Company Report

Pages: 9

Price: 24.95

Company: Gilead Sciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 470

01/26/2011

Company Report

Pages: 8

Snag in Regulatory Process

Provider: BWS Financial

Analyst: KHORSAND H

Price: 25.00

Research Provided by a Third Party

Company: Gilead Sciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 471

01/26/2011

Company Report

Pages: 14

In-line Q4:10; Our Thoughts on 2011 Business Outlook

Provider: WEDBUSH SECURITIES INC.

Analyst: XU Y

Price: 50.00

Research Provided by a Third Party

Company: Gilead Sciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 472

01/24/2011

Company Report

Pages: 8

Q4:10 Preview; Expect an In-Line Quarter

Provider: WEDBUSH SECURITIES INC.

Analyst: XU Y

Price: 25.00

Research Provided by a Third Party

Company: Gilead Sciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 473

01/14/2011

Industry Report

Pages: 5

LIFE SCIENCES -The Week Ahead in Life Sciences - Upcoming Events for the Week of January 16

Provider: WEDBUSH SECURITIES INC.

Price: 10.00

Research Provided by a Third Party

Company: Gilead Sciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 474

01/09/2011

Industry Report

Pages: 5

2011 - Competition and Complexity Intensify for HCV

Provider: WEDBUSH SECURITIES INC.

Analyst: XU Y

Price: 10.00

Research Provided by a Third Party

Company: Gilead Sciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 475

12/06/2010

Company Report

Pages: 9

Price: 24.95

Company: Gilead Sciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 476

11/12/2010

Industry Report

Pages: 4

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Price: 10.00

Research Provided by a Third Party

Company: Gilead Sciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 477

11/08/2010

Industry Report

Pages: 19

Wrapping Up AASLD 2010 with Dr. Zeuzem

Provider: WEDBUSH SECURITIES INC.

Analyst: XU Y

Price: 50.00

Research Provided by a Third Party

Company: Gilead Sciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 478

11/01/2010

Company Report

Pages: 9

HCV Strategy Unveiled at AASLD

Provider: WEDBUSH SECURITIES INC.

Analyst: XU Y

Price: 25.00

Research Provided by a Third Party

Company: Gilead Sciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 479

10/26/2010

Company Report

Pages: 9

Price: 24.95

Company: Gilead Sciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 480

10/22/2010

Company Report

Pages: 14

Slowdown in HIV franchise, unfavorable healthcare reforms, currency fluctuations & volatile royalty revenue expected to significantly impact growth prospects...

Provider: WEDBUSH SECURITIES INC.

Price: 50.00

Research Provided by a Third Party